Atea Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Atea Pharmaceuticals, Inc. - common stock (AVIR)
US:NASDAQ Investor Relations:
investors.aviragentherapeutics.com/news-releases/news-release-details/aviragen-therapeutics-and-vaxart-enter-merger-agreement
Company Research
Source: Yahoo! Finance
trials (C-BEYOND — enrollment complete, mid-2026 readout; C-FORWARD — enrollment through mid-2026, year-end readout) testing bemnifosbuvir/ruzasvir versus sofosbuvir/velpatasvir with 1,760 patients and SVR24 as the primary endpoint. HEV pipeline expansion — AT-587 selected: Atea picked AT-587 as its lead HEV candidate after promising preclinical potency, PK and safety data, plans first-in-human studies mid-2026 with proof-of-concept targeted by year-end, and estimates a $750M–$1B annual market opportunity in immunocompromised patients. Financial and commercial positioning: The company ended 2025 with $301.8 million in cash and says its runway extends through 2027 while focusing spending on HCV Phase 3 and pre-launch activities, plans a ~75-person U.S. commercial team, and has milestone/royalty obligations to Merck tied to NDA submission/approval. Interested in Atea Pharmaceuticals, Inc.? Here are five stocks we like better. Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress
Show less
Read more
Impact Snapshot
Event Time:
AVIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVIR alerts
High impacting Atea Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
AVIR
News
- Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026 [Yahoo! Finance]Yahoo! Finance
- Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026GlobeNewswire
AVIR
Earnings
- 3/5/26 - Miss
AVIR
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/9/26 - Form SCHEDULE
- AVIR's page on the SEC website